Icrucumab

Icrucumab(IMC-18F1) is a human monoclonal antibody designed for the treatment of solid tumors.^[1]^[2]

Icrucumab was developed by ImClone Systems Inc. It is undergoing Phase I trials.^[3]

References

^"Statement On A Nonproprietary Name Adopted By The USAN Council: Icrucumab"(PDF).American Medical Association.
^LoRusso PM, Krishnamurthi S, Youssoufian H, Hall N, Fox F, Dontabhaktuni A, Grebennik D, Remick S (April 2014). "Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study".Invest New Drugs.32(2): 303–11.doi:10.1007/s10637-013-9998-8.PMID 23903897.S2CID 34756277.
^Clinical trial numberNCT00782002for "Safety Study of IMC-18F1, to Treat Advanced Solid Tumors in Subjects That no Longer Respond to Standard Therapy" atClinicalTrials.gov

Thismonoclonal antibody–related article is astub.You can help Wikipedia byexpanding it.